BMS-986012, an Anti–Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study
Titel:
BMS-986012, an Anti–Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study
Auteur:
Chu, Quincy Leighl, Natasha B. Surmont, Veerle van Herpen, Carla Sibille, Anne Markman, Ben Clarke, Stephen Juergens, Rosalyn A. Rivera, Mirelis Acosta Andelkovic, Vladimir Rudin, Charles M. Snow, Stephanie Kim, Dong-Wan Sanatani, Michael Lin, Hongxia Sanghavi, Kinjal Tannenbaum-Dvir, Sarah Basciano, Paul Lathers, Deanne Urbanska, Katarzyna Kollia, Georgia He, Chunsheng DiPiero, Andrew Liu, Yu Ready, Neal